United States · FDA National Drug Code directory
Adbry
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50222-350_8abedac8-f75e-42a0-8591-10fabcf41fb5
- Product NDC
- 50222-350
- Form
- INJECTION, SOLUTION
- Composition / generic term
- tralokinumab-ldrm
- Labeler
- LEO Pharma Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240701
- Source listing expiry
- 20261231
Source-listed ingredients
- TRALOKINUMAB — 300 mg/2mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE, GLASS in 1 CARTON (50222-350-01) / 2 mL in 1 SYRINGE, GLASS (50222-350-00) · 50222-350-01
- 2 SYRINGE, GLASS in 1 CARTON (50222-350-02) / 2 mL in 1 SYRINGE, GLASS (50222-350-00) · 50222-350-02
- 1 SYRINGE, GLASS in 1 CARTON (50222-350-91) / 2 mL in 1 SYRINGE, GLASS (50222-350-90) · 50222-350-91
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →